HUMAN AMYLOID IMAGING CONFERENCE
January 17-19, 2018
Funding for this conference is made possible, in part by 1 R13 AG042201 from The National Institute on Aging. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
The Tau Consortium is an innovative medical research program that is operated under the auspices of the Rainwater Charitable Foundation. The Consortium commissions world-class basic research and drug discovery to treat and prevent Alzheimer’s, progressive supranuclear palsy (PSP), and other tauopathies. The Tau Consortium acts with urgency and with patients in mind. It ensures that its members work collaboratively and engage with partners who can accelerate their progress. Since founding the Tau Consortium in 2009, the Rainwater Charitable Foundation has committed nearly $100 million to the program. There are currently five treatments in human trials as a result of the Rainwater family’s funding. Please visit http://tauconsortium.org for more information.